N-(4-bromophenyl)-3-(trifluoromethyl)benzamide | 562080-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-bromophenyl)-3-(trifluoromethyl)benzamide
• CAS: 562080-79-9
• 化学式: C₁₄H₉BrF₃NO
• 分子量: 344.131
• InChiKey: JDUHFWWSDVISOZ-UHFFFAOYSA-N

物化性质

• 保留指数：
  2201

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-bromophenyl)-3-(trifluoromethyl)benzamide 在 水 、 palladium diacetate 、 三乙胺 、 sodium hydroxide 、 2-(二叔丁基膦)联苯 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 36.5h， 生成 (E)-3-(4-(3-(trifluoromethyl)benzamido)phenyl)acrylic acid
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR TREATING CANCER

  摘要：

  提供了替代肉桂酰胺化合物和类似物、制备这类化合物的方法、包含这类化合物的药物组合物和药物、以及使用这类化合物治疗、预防或改善癌症的方法。

  公开号：

  US20200299282A1
• 作为产物：
  描述：

  3-三氟甲基苯甲酸 、 4-溴苯胺 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以98%的产率得到N-(4-bromophenyl)-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR TREATING CANCER

  摘要：

  提供了替代肉桂酰胺化合物和类似物、制备这类化合物的方法、包含这类化合物的药物组合物和药物、以及使用这类化合物治疗、预防或改善癌症的方法。

  公开号：

  US20200299282A1

文献信息

• Phosphate transport inhibitors
  申请人：GelTex Pharmaceuticals, Inc.

  公开号：US20040019113A1

  公开（公告）日：2004-01-29

  Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar 1 —W—X—Y—Ar 2 ; or a pharmaceutically acceptable salt thereof. Ar 1 and Ar 2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.

  本文披露了被识别为磷酸盐转运抑制剂的化合物。许多化合物由结构式(I)表示：Ar1—W—X—Y—Ar2；或其药用可接受的盐。Ar1和Ar2独立地是取代或未取代的芳基或可取代的五元或六元非芳香杂环基与可取代的单环芳基融合。W和Y独立地是共价键或C1-C3取代或未取代的烷基基团。X是含杂原子的官能团、芳香杂环基、取代芳香杂环基、非芳香杂环基、取代非芳香杂环基、烯烃基或取代烯烃基。还披露了治疗与高磷血症相关疾病以及磷酸盐转运功能介导的疾病的方法。该方法包括给予上述化合物之一的有效量。
• Six membered heteroaromatic inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070149508A1

  公开（公告）日：2007-06-28

  A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.

  提供了一种化合物，其一般结构为(A)：其中A是(未)取代芳基或(未)取代杂环芳基基团，G是N、CH或CR，R是未取代或取代的较低烷基，Y是疏水连接基团，L是定义的取代基。化合物(A)可用于治疗各种与血管生成和血液学有关的疾病，例如在不对包括给予批准药物的激酶抑制治疗做出反应的患者中的骨髓增生性疾病。
• PHOSPHATE TRANSPORT INHIBITORS
  申请人：GENZYME CORPORATION

  公开号：EP1465638A2

  公开（公告）日：2004-10-13
• US7119120B2
  申请人：——

  公开号：US7119120B2

  公开（公告）日：2006-10-10
• [EN] PHOSPHATE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU PHOSPHATE
  申请人：GENZYME CORP

  公开号：WO2003057225A2

  公开（公告）日：2003-07-17

  Disclosed are compounds, which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar1-W-X-Y-Ar2; or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C 1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.